Vineet Laboratories Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Vineet Laboratories's earnings have been declining at an average annual rate of -3.1%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 31.9% per year. Vineet Laboratories's return on equity is 0.4%, and it has net margins of 0.1%.
Anahtar bilgiler
-3.1%
Kazanç büyüme oranı
-1.5%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | -31.9% |
| Özkaynak getirisi | 0.4% |
| Net Marj | 0.1% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt
Jul 12
Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive
Mar 07We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt
Feb 15With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case
Nov 14Gelir ve Gider Dağılımı
Vineet Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 1,369 | 1 | 65 | 0 |
| 31 Mar 24 | 1,510 | 10 | 65 | 0 |
| 31 Dec 23 | 1,707 | 27 | 62 | 0 |
| 30 Sep 23 | 2,049 | 61 | 64 | 0 |
| 30 Jun 23 | 2,010 | -10 | 62 | 0 |
| 31 Mar 23 | 2,123 | 13 | 61 | 0 |
| 31 Dec 22 | 2,107 | 10 | 56 | 0 |
| 30 Sep 22 | 1,823 | 10 | 47 | 0 |
| 30 Jun 22 | 1,823 | 64 | 46 | 0 |
| 31 Mar 22 | 1,912 | 66 | 58 | 0 |
| 31 Mar 21 | 2,435 | 18 | 56 | 0 |
Kaliteli Kazançlar: VINEETLAB has high quality earnings.
Büyüyen Kar Marjı: VINEETLAB became profitable in the past.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VINEETLAB's earnings have declined by 3.1% per year over the past 5 years.
Büyüme Hızlandırma: VINEETLAB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Kazançlar vs. Sektör: VINEETLAB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Özkaynak Getirisi
Yüksek ROE: VINEETLAB's Return on Equity (0.4%) is considered low.